Lamark Biotech raises Rs 6.5 crore in a pre-Series A funding round led by IAN Group to accelerate its thermostable insulin program and expand its innovative biologics platform.

Jul 01, 2025•about 1 month ago

Amount Raised

₹65 Million

Round Type

PRE-SERIES A

BengaluruBiotechnology

Investors

Venkataraman KnkDr. Nita RoyDr. Vinayender TullaIan Alpha FundIan Group

Description

Lamark Biotech, an innovation-led biopharma startup, raised Rs 6.5 crore in pre-Series A funding led by IAN Group. The funds will be used to accelerate their thermostable insulin program and expand their ProteoStrong platform for critical therapeutics. Founded in 2018, Lamark aims to provide accessible biologics in low-resource environments. This investment aligns with IAN's strategy to support innovations that address real-world problems.

Company Information

Company

Lamark Biotech

Location

Bengaluru, Karnataka, India

About

Lamark Biotech is an innovation-led biopharma startup that reimagines drug delivery for chronic and life-altering diseases. Founded in 2018 by Dr. Vaibhav Bhatia, the company utilizes its proprietary ProteoStrong platform to stabilize fragile protein-based drugs without altering their molecular structure. It aims to reduce cold-chain dependency in biologics, making critical treatments more accessible. Lamark is actively pursuing advancements in biologics, including a new class of temperature-resilient products.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends